Lobectomy for Lung Cancer: 165 Real Stories

165 stories match lung cancer and lobectomy. 77 of them mention chemotherapy.

Cancer Stories

Roxanne, who was diagnosed with Stage III Lung CancerLung Cancer

Stage III EGFR Lung Cancer: Roxanne's Patient Story

Patient Info: Roxanne, Female, 40s | Stage III

Biomarkers: EGFR mutation

Roxanne had Stage III EGFR-mutated lung cancer after surgery found mediastinal lymph-node involvement. As of March 2026, she was living with the long-term effects of surgery, chemotherapy, radiation, and ongoing EGFR-targeted therapy, while also managing the emotional and financial burden of cancer as a single parent.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Prior Stage IA lung adenocarcinoma with fungal airway disease mimicking recurrence

Patient Info: Anonymized, Female, 70+ | Stage I

Her prior Stage IA lung adenocarcinoma was surgically treated without adjuvant therapy, and later pulmonary lesions were attributed to allergic bronchopulmonary mycosis rather than cancer recurrence; symptoms and imaging improved after antifungal and inhaled therapy.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Lung CancerLung Cancer

Pulmonary epithelioid hemangioendothelioma with complete response after neoadjuvant therapy

Patient Info: Anonymized, Male, 60s

Biomarkers: WWTR1-CAMTA1 fusion; vascular markers supported epithelioid hemangioendothelioma; lung cancer markers were absent.

The patient achieved radiographic disappearance of the lung tumor after neoadjuvant paclitaxel/carboplatin plus bevacizumab. Surgery then showed no residual tumor and lymph nodes were negative; CT follow-up through April 2024 showed no recurrence.

PubMed Central
OutcomeCancer-Free / NED
Taylor, who was diagnosed with Stage I Lung CancerLung Cancer

Stage I Lung Cancer: Taylor's Survivor Story

Patient Info: Taylor, Female, Under 40 | Stage I

Taylor had a Stage IB 4 cm lung carcinoid tumor removed surgically with clean margins at age 21. She did not need chemotherapy or radiation and was 18 years post-diagnosis as of February 2026.

The Patient Story
OutcomeCancer-Free / NED
Ruchira, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Ruchira's Survivor Story

Patient Info: Ruchira, Female | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Not reported

Although the disease progressed to Stage IV after lobectomy, ALK testing led to lorlatinib; she reported no evidence of disease after 3 months and continued daily targeted therapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

MET exon 14 skipping lung adenocarcinoma: sequential MET-TKI toxicity and ongoing chemotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; EGFR negative; ALK negative; ROS1 negative; PD-L1 tumor proportion score 10%

Metastatic Site: pleura

The cancer recurred with pleural dissemination after surgery and adjuvant UFT. Sequential MET inhibitors and systemic therapies provided periods of disease control but were limited by ILD and non-ILD toxicities; at the report, he remained on carboplatin, pemetrexed, and bevacizumab.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA KRAS/STK11/TP53-mutated lung adenocarcinoma: fatal pembrolizumab-induced myocarditis after adjuvant therapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Ki-67 20-25%; PD-L1 expression 10%; KRAS exon 2 mutation; STK11 mutation; TP53 mutation

As of December 2025, he had died after 15 days of hospitalization from sepsis and multi-organ failure following severe pembrolizumab-induced myocarditis after adjuvant treatment for resected Stage IIIA lung adenocarcinoma.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Stage IA1 lung adenocarcinoma: disease-free after VATS right lower lobectomy

Patient Info: Anonymized, Male, 70+

Biomarkers: No molecular biomarkers reported; final pathology pT1aN0M0 with no lymph node metastases

Final pathology showed pT1aN0M0 Stage IA1 lung adenocarcinoma with no lymph node metastases, and he remained disease-free at 1-year follow-up.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Second primary Stage I lung adenocarcinoma treated with segmentectomy and adjuvant pembrolizumab

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: PD-L1 <1%; no common targetable lung cancer changes found in EGFR, ALK, KRAS, BRAF, MET, PIK3CA, RET, ROS1, or NTRK.

At 6-month oncologic follow-up, PET-CT showed complete metabolic response with no evidence of residual disease after segmentectomy and adjuvant pembrolizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA KRAS p.G12V lung adenocarcinoma: pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: KRAS p.G12V mutation; PD-L1 0% tumor-cell staining; <1% tumor-associated inflammatory-cell staining; no EGFR, ALK, or ROS1 driver mutation reported

Pathology after lobectomy showed a pathologic complete response, and surveillance imaging 12 months later showed no evidence of disease recurrence.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA lung adenocarcinoma complicated by severe atezolizumab-induced liver toxicity

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: PD-L1 49%; case text describes triple-negative status without expanding the specific markers

The patient was discharged clinically stable but with guarded prognosis after atezolizumab-induced vanishing bile duct syndrome, requiring prednisone, mycophenolate mofetil, ursodeoxycholic acid, prophylaxis, and close oncology/internal medicine follow-up.

PubMed Central
OutcomeCare Ongoing